Pfiz­er re-ups on Mis­sion Ther­a­peu­tics col­lab­o­ra­tion, lead­ing a $15M round and grab­bing first dibs on DUBs

Sev­en years af­ter Pfiz­er first in­vest­ed in Mis­sion Ther­a­peu­tics, a biotech that re­search­es se­lec­tive­ly in­hibit­ing deu­biq­ui­ty­lat­ing en­zymes (DUBs), the phar­ma gi­ant is re-up­ping its com­mit­ment to the com­pa­ny in an­oth­er sign of con­fi­dence in the field of pro­tein degra­da­tion.

Pfiz­er’s VC arm is head­ing up a $15 mil­lion round, an­nounced Mon­day morn­ing, and in­creas­ing its over­all stake in Mis­sion. Pfiz­er is al­so en­ter­ing in­to a li­cens­ing agree­ment that would give it first dibs at ne­go­ti­at­ing ex­clu­siv­i­ty af­ter ac­cess­ing cer­tain DUB in­hibitors and screen­ing them for their po­ten­tial as drugs.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.